The medicine province is coming! 400 million market pattern reshaping, 22 varieties "rush to the examination field", the opening time or forward?

Recently, a notice on the procurement data related to the scope of the first batch of continuous and third batch of drug collection varieties of public medical institutions in Zhejiang Province (hereinafter referred to as the reporting notice) was circulated

The situation of "only the low price is selected" is no longer the case, and the advantages of the "double envelope" model are highlighted

Since 2020, the provincial/provincial alliance has blossomed everywhere and blossomed, and various localities have successively carried out various special collections of injections, insulin, antibacterial drugs and other special collections according to their actual conditions, and the procurement rules and selection models have also been similar and similar

As far as Zhejiang Province is concerned, its innovation is that the varieties included in the procurement with quantity are divided into group A (original research drugs or reference preparations, generic drugs that have passed the consistency evaluation) and group B (other generic drugs), that is, the "double envelope" model, such as any one of the two groups of flow standards in A and B, then 50% of the agreed procurement volume of the group is merged into the agreed procurement volume of the other group, and the remaining 50% is used as the remaining amount in addition to the agreed purchase amount

● In terms of agreed procurement volume - each variety is based on 60% of the total annual drug consumption of all public medical institutions in the province in 2021, which is divided into three situations:

(1) Both groups were selected: the agreed procurement volume of Group A and Group B was determined according to its procurement share of all public medical institutions in the province in 2021 (the highest and lowest agreed procurement amounts were 50% and 10% of the total annual drug consumption of the variety, respectively);

(2) Any group of no selected drugs in the two groups A and B: 50% of the agreed procurement volume of the group is merged into another group, and the remaining 50% is used as the remaining amount other than the agreed purchase amount;

(3) Either group in A and B only receives 50% of the original agreed procurement volume: half of the other 50% of the original agreed procurement volume of the group is merged into the other group, and the remaining half is used as the remaining amount other than the agreed purchase amount

● Procurement rules - the third batch of the technical review part is roughly the same as the second batch, with a total of 6 indicators, including clinical use efficacy, quality reliability, clinical use safety, brand recognition, packaging quality and convenience, service reputation, etc

Technical Review Score Table

According to the expert scoring score, the highest and lowest scores are removed, and the average score (rounded to retain 2 decimal places) is used as the expert review result

Shortlisted price review enterprises

The price review part is also similar to the second batch of collection and procurement, which is divided into two situations: the number of reporting enterprises = 1, the number of declaring enterprises ≥ 2, and the specific details of the proposed selection are shown in the following figure:

Detailed rules for the proposed selection of price reviews

The third batch of collective procurement in Zhejiang Province will follow the "double envelope" model that combines technical review and price review for centralized procurement

In addition, it is worth noting that the "Reporting Notice" requires medical institutions to scientifically and accurately report the amount according to the changes in the drug structure, the adjustment of medical insurance payment policies and other factors, and if the amount of filling in the report increases by 100% or decreases by 20% compared with the actual purchase (distribution), the system will do early warning prompts

400 million market reshuffle! Rabeprazole, cefotaxime.

The first batch of selected catalogues of drug collection in Zhejiang Province

The second batch of drugs in Zhejiang Province is selected in the catalogue

Source: Zhejiang Pharmaceutical Equipment Procurement Center official website

As one of the first batch of products to collect and open bids, rabeprazole sodium enteric-coated tablets increased by 45.

The sales of cefotaxime sodium for injection in Zhejiang Province in 2021 increased by 70.

Another best-selling product, loratadine cidiprodine tablets, increased by 34.

Hisco has two products selected in the second batch of collection, of which the sales of nalmefine hydrochloride injection in zhejiang province public hospital terminals in 2021 increased by 8.

In recent years, the terminal sales scale of public hospitals in Zhejiang Province (unit: 100 million yuan)

Source: Intranet key provinces and cities public hospital terminal competition pattern

According to data from the intranet, in the terminals of public hospitals in key provinces and cities, the sales of Zhejiang Province in 2020 and 2021 will average more than 10 billion yuan

The third batch of collection is on the road, and 22 varieties such as lansoprazole and leuprolide are to be included

Judging from the timeline of drug collection and procurement in Zhejiang Province in recent years, the first two batches are released for comment in October of each year, the list of varieties to be selected in December, and the results

It was learned from the "Reporting Notice" that 22 chemical drugs such as lansoprazole and leuprolide (including the first batch of uncondated varieties, the same below) are planned to be included in the third batch of drug collection in Zhejiang Province, while 10 biological drugs such as growth hormone previously transmitted on the Internet have not appeared in the list of collections and reports in
this batch.

List of the third batch of varieties collected in Zhejiang Province

According to the data of the intranet, the sales scale of 22 varieties in the terminals of public hospitals in Zhejiang Province in 2021 will be close to 400 million yuan; From the perspective of treatment categories, digestive system and metabolic drugs occupy 10 seats, cardiovascular and cerebrovascular system drugs and systemic anti-infective drugs have 3 each, and anti-tumor and immunomodulators and nervous system drugs have 2 respectively
.

It is proposed to include the evaluation of the third batch of collected varieties (including the approval of the new registration classification).

Note: The varieties that are not listed have not been evaluated by enterprises

Source: MED2.
0 China Drug Review Database

Judging from the evaluation, in addition to amoxicillin sodium clavulanate potassium for injection, triprilin acetate injection and lactulose oral solution, most of the varieties to be included in this batch of collections have not yet been evaluated
by enterprises.

In fact, the collection of provincial/inter-provincial alliances is more like a supplement to the national procurement, the "baton bearer" of market resource redistribution; The implementation and promotion of the provincial/inter-provincial alliance set reflects the guiding principle
of "adhering to quantity procurement, ensuring quality, promoting innovation-driven, stabilizing supply, ensuring clinical use, and setting bidding rules for specific varieties and competitive patterns" put forward by the state.